Blood pressure and proinflammatory marker dynamics after renal denervation in patients with resistant hypertension and various severity of coronary atherosclerosis

Introduction. Patients with resistant hypertension (RH) associated with coronary heart disease (CHD) and, in particular, with an unfavorable course of coronary atherosclerosis have the highest risk of cardiovascular complications. Tumor necrosis factor-alpha (TNF-α) and high-sensitivity C-reactive protein (hs-CRP) were shown to play a role of independent predictors for the development of such complications. However, the changes in these markers and blood pressure (BP) due to renal denervation (RDN) have not been a subject of investigation in this patient group yet.
Objectives. To study changes in BP and proinflammatory markers in patients with RH and CHD after RDN and to compare the indicators depending on the severity of coronary atherosclerosis.
Material and Methods. The study analyzed case histories of 35 patients with RH and CHD who underwent a full clinical, instrumental, and laboratory examination before and one year after RDN.
Results. We observed a reduction of average 24-hour blood pressure by 15 (0–21) / 7(–3–14) mmHg (p < 0.05), a decrease in TNF-α from 7.8 (6.3; 9.6) to 7.3 (6.8; 8.6) pg/mL (p = 0.044), and a downward trend of hs-CRP values from 2.4 (1.4; 6.0) to 1.8 (1.3; 3.6) mg/L (p = 0.186). Group of patients with unfavorable course of coronary atherosclerosis had higher levels of TNF-α initially (р = 0.040) and a year after RDN (р = 0.038), but no significant changes in BP were observed.
Conclusions. Obtained data suggested that the antihypertensive effect of RDN was less pronounced in patients with an unfavorable course of coronary atherosclerosis.

resistant hypertension, renal denervation, coronary atherosclerosis, high-sensitivity C-reactive protein, tumor necrosis factor-alpha

1. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J. et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765–774.

2. Virdis A., Dell’Agnello U., Taddei S. Impact of inflammation on vascular disease in hypertension. Maturitas. 2014;78(3):179–183. DOI: 10.1016/j.maturitas.2014.04.012.

3. Vasilec L.M., Grigoriadi N.E., Gordijchuk R.N., Karpunina N.S., Shcherbenev V.M. The prognostic significance of systemic inflammation factors in patients with coronary heart disease. Siberian Medical Journal (Irkutsk). 2013;116(1):50–52 (In Russ.).

4. Zyubanova I.V., Mordovin V.F., Falkovskaja A.Y., Pekarsky S.E. Changes in ambulatory blood pressure monitoring data after renal denervation: 12-month follow-up. The Siberian Medical Journal. 2015;30(3):41–44 (In Russ.). DOI: 10.29001/2073-8552-2015-30-3-41-44.

5. Ripp T.M., Mordovin V.F., Pekarskiy S.E., Ryabova T.P., Zlobina M.Z., Semke G.V. et al. Cardioprotective effects of renal denervation in resistant hypertension: efficiency predictors. Arterial Hypertension. 2014;20(6):559–567 (In Russ.). DOI: 10.18705/1607-419X-2014-20-6-559-567.

6. Falkovskaya A.Y., Mordovin V.F., Pekarskiy S.E., Baev A.E., Semke G.V., Ripp T.M. et al. Transcatheter renal denervation in patients with resistant hypertension and type 2 diabetes mellitus has beneficial effects beyond blood pressure reduction. Arterial Hypertension. 2014;20(2):107–112 (In Russ.). DOI: 10.18705/1607-419X-2014-20-2-107-112.

7. Mahfoud F., Böhm M., Schmieder R., Narkiewicz K., Ewen S., Ruilope L. et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. European Heart Journal. 2019;21:ehz118. DOI: 10.1093/eurheartj/ehz118.

8. Atti V., Turagam M.K., Garg J., Lakkireddy D. Renal sympathetic denervation improves clinical outcomes in patients undergoing catheter ablation for atrial fibrillation and history of hypertension: A meta-analysis. J. Cardiovasc. Electrophysiol. 2019;30(5):702–708. DOI: 10.1111/jce.13868.

9. Gao J.Q., Yang W., Liu Z. Percutaneous renal artery denervation in patients with chronic systolic heart failure: a randomized controlled trial. Cardiol. J. 2018;3. DOI: 10.5603/CJ.a2018.0028.

10. Dörr O., Liebetrau C., Möllmann H., Mahfoud F., Ewen S., Gaede L. et al. Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension. Clin. Res. Cardiol. 2015;104(2):175–184. DOI: 10.1007/s00392-014-0773-4.

11. Kablak-Ziembicka A., Przewlocki T., Sokołowski A., Tracz W., Podolec P. Carotid intima-media thickness, hs-CRP and TNF-α are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis. 2011;214(1):185–190. DOI: 10.1016/j.atherosclerosis.2010.10.017.

12. Kotchen T.A. Hypertensive vascular diseases. In: Kasper D., Fauci A., Hauser S., Longo D., Jameson J., Loscalzo J., editors. Harrison’s principles of internal medicine. New York: McGraw-Hill; 2015:1611–1626.

13. Völz S., Svedlund S., Andersson B., Li-Ming G., Rundqvist B. Coronary flow reserve in patients with resistant hypertension. Clin. Res. Cardiol. 2017;106(2):151–157. DOI: 10.1007/s00392-016-1043-4.

14. Gonçalves I., Edsfeldt A., Colhoun H.M. , Shore A.C., Palombo C., Natali A. et al. SUMMIT consortium. Association between renin and atherosclerotic burden in subjects with and without type 2 diabetes. BMC Cardiovasc. Disord. 2016;171. DOI: 10.1186/s12872-016-0346-8.

15. Zhu M., Lin J., Wang C., Yang M., Lv H., Yang M. et al. The relationship among angiotensinogen genes polymorphisms and hs-CRP and coronary artery disease. J. Clin. Lab. Anal. 2019;33(5):e22881. DOI: 10.1002/jcla.22881.

16. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999;340(2):115–126.

17. Yu X., Yang Z., Yu M. Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage. Ren. Fail. 2010;32(4):475–479. DOI: 10.3109/08860221003664280.

18. Fon Tacer K., Kuzman D., Seliskar M., Pompon D., Rozman D. TNF-alpha interferes with lipid homeostasis and activates acute and proatherogenic processes. Physiol. Genomics. 2007;31(2):216–227. DOI: 10.1152/physiolgenomics.00264.2006.

19. Tajfard M., Tavakoly Sany S.B., Avan A., Latiff L.A., Rahimi H.R., Moohebati M. et al. Relationship between serum high sensitivity C-reactive protein with angiographic severity of coronary artery disease and traditional cardiovascular risk factors. J. Cell Physiol. 2019;234(7):10289–10299. DOI: 10.1002/jcp.27945.

20. Tan Z., Li L., Ma Y., Geng X. Clinical significance of cys-C and hs-CRP in coronary heart disease patients undergoing percutaneous coronary intervention. Braz. J. Cardiovasc. Surg. 2019;34(1):17–21. DOI: 10.21470/1678-9741-2018-0171.

21. Yao W., Wang N., Qian J., Bai L., Zheng X., Hou G. et al. Renal sympathetic denervation improves myocardial apoptosis in rats with isoproterenol-induced heart failure by downregulation of tumor necrosis factor-α and nuclear factor-κB. Exp. Ther. Med. 2017;14(5):4104–4110. DOI: 10.3892/etm.2017.5066.

22. Liu Q., Zhang Q., Wang K., Wang S., Lu D., Li Z. et al. Renal denervation findings on cardiac and renal fibrosis in rats with isoproterenol induced cardiomyopathy. Sci. Rep. 2015;5:18582. DOI: 10.1038/srep18582.

23. Falkovskaya A.Y., Mordovin V.F., Pekarsky S.Y., Bayev A.Y., Semke G.V., Ripp T.M. et al. Dynamics of glycemic control after renal denervation in patients with resistant hypertension and type 2 diabetes mellitus. Bulletin of Siberian Medicine. 2015;14(5):82–90 (In Russ.). DOI: 10.20538/1682-0363-2015-5-82-90.

24. Barcelos A.L.V., de Oliveira E.A., Haute G.V., Costa B.P., Pedrazza L., Donadio M.V.F. et al. Association of IL-10 to coronary disease severity in patients with metabolic syndrome. Clin. Chim. Acta. 2019;495:394–398. DOI: 10.1016/j.cca.2019.05.006.